Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew L Mellor

Showing results (41-50 of 110) with videos related to

Pageof 11
Sort By:
Immunity|May 17, 2005
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenaseDavid H Munn, Madhav D Sharma, Babak Baban, et al.
Infection and Immunity|April 23, 2008
Deficiency of indoleamine 2,3-dioxygenase enhances commensal-induced antibody responses and protects against Citrobacter rodentium-induced colitisLynne Harrington, Chittur V Srikanth, Reuben Antony, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 29, 2009
IDO activates regulatory T cells and blocks their conversion into Th17-like T cellsBabak Baban, Phillip R Chandler, Madhav D Sharma, et al.
Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery|May 30, 2021
The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic reviewDaniel J Lin, James C K Ng, Lei Huang, et al.
Journal for Immunotherapy of Cancer|August 28, 2020
Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunityHenrique Lemos, Rong Ou, Caroline McCardle, et al.
Cancer Letters|July 30, 2019
Adoptive CD8<sup>+</sup> T cell therapy against cancer:Challenges and opportunitiesXiaotao Jiang, Jiang Xu, Mingfeng Liu, et al.
Blood|December 14, 2007
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethalityLisa K Jasperson, Christoph Bucher, Angela Panoskaltsis-Mortari, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 12, 2014
TLR2-dependent activation of β-catenin pathway in dendritic cells induces regulatory responses and attenuates autoimmune inflammationIndumathi Manoharan, Yuan Hong, Amol Suryawanshi, et al.
International Immunology|June 22, 2005
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligationBabak Baban, Anna M Hansen, Phillip R Chandler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansionAndrew L Mellor, Babak Baban, Phillip Chandler, et al.
Pageof 11

Showing results (41-50 of 110) with videos related to

Sort By:
Pageof 11
Immunity|May 17, 2005
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenaseDavid H Munn, Madhav D Sharma, Babak Baban, et al.
Infection and Immunity|April 23, 2008
Deficiency of indoleamine 2,3-dioxygenase enhances commensal-induced antibody responses and protects against Citrobacter rodentium-induced colitisLynne Harrington, Chittur V Srikanth, Reuben Antony, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 29, 2009
IDO activates regulatory T cells and blocks their conversion into Th17-like T cellsBabak Baban, Phillip R Chandler, Madhav D Sharma, et al.
Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery|May 30, 2021
The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic reviewDaniel J Lin, James C K Ng, Lei Huang, et al.
Journal for Immunotherapy of Cancer|August 28, 2020
Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunityHenrique Lemos, Rong Ou, Caroline McCardle, et al.
Cancer Letters|July 30, 2019
Adoptive CD8<sup>+</sup> T cell therapy against cancer:Challenges and opportunitiesXiaotao Jiang, Jiang Xu, Mingfeng Liu, et al.
Blood|December 14, 2007
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethalityLisa K Jasperson, Christoph Bucher, Angela Panoskaltsis-Mortari, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 12, 2014
TLR2-dependent activation of β-catenin pathway in dendritic cells induces regulatory responses and attenuates autoimmune inflammationIndumathi Manoharan, Yuan Hong, Amol Suryawanshi, et al.
International Immunology|June 22, 2005
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligationBabak Baban, Anna M Hansen, Phillip R Chandler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansionAndrew L Mellor, Babak Baban, Phillip Chandler, et al.
Pageof 11